AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6210562
Drug: Mezlocillin 1
RxNorm normalized name: mezlocillin 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin 1 g
Trial: 6210562
Drug: Mezlocillin 3
RxNorm normalized name: mezlocillin 3 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin 3 g
Trial: 6210562
Drug: Mezlocillin 5
RxNorm normalized name: Mezlocilline
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mezlocillin 5 g
Trial: 30694322
Drug: Hydrocortisone (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (cumulative dose, 72.5 mg/kg)
Trial: 23701917
Drug: GSK256066 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256066 25 μg
Trial: 23701917
Drug: GSK256066 87.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256066 87.5 μg
Trial: 16757200
Drug: Stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stannous fluoride gel (control group)
Trial: 16757200
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stannous fluoride gel)
Trial: 1772463
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg t.i.d. for 24 weeks
Trial: 27138789
Drug: 25(OH)D (≥30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D (≥30 ng/mL)
Trial: 25132143
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of 400 mg oral zinc sulfate with podophyllin
Trial: 25132143
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of 400 mg oral zinc sulfate with imiquimod
Trial: 25132143
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of 400 mg oral zinc sulfate with cryotherapy
Trial: 22035976
Drug: Collagen/thrombin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen/thrombin and autologous platelet hemostatic agent (standard hemostasis plus study product)
Trial: 12152252
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day p.o. aspirin for 3 days
Trial: 12152252
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day p.o. aspirin for 3 days
Trial: 30669202
Drug: Clarithromycin 250mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250mg/day + Budesonide nasal spray once a day
Trial: 30669202
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray once a day
Trial: 25453593
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) - 12 daily exposures to vegetable puree added to milk (days 1-12), then 12 x 2 daily exposures to vegetable puree added to rice (days 13-24)
Trial: 25453593
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - Plain milk and rice given, followed by 11 daily exposures to vegetable puree
Trial: 25453593
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 11 daily exposures to vegetable puree after initial interventions
Trial: 19636603
Drug: Watercress extract
RxNorm normalized name: watercress allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watercress extract (WCE) 0.1-10 microL/mL
Trial: 19636603
Drug: Watercress consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watercress consumption (85 g per day for 8 weeks)
Trial: 15497672
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Seralin)
Trial: 11301561
Drug: (R)-albuterol 5
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-albuterol 5 mg
Trial: 11301561
Drug: (S)-albuterol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-albuterol 1.25 mg
Trial: 11301561
Drug: (R)-albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-albuterol
Trial: 11301561
Drug: (RS)-albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (RS)-albuterol
Trial: 11301561
Drug: (R)-albuterol and
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-albuterol and (RS)-albuterol
Trial: 11301561
Drug: (S)-albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-albuterol
Trial: 8148281
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) 5 mg/kg/day
Trial: 8148281
Drug: Continuous reducing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous reducing dose of CyA (1 mg/kg/day)
Trial: 8148281
Drug: Intermittent fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent fixed dose of CyA (5 mg/kg every fifth day)
Trial: 3211287
Drug: oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral scopolamine 0.3 mg
Trial: 3211287
Drug: oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral scopolamine 0.6 mg
Trial: 3211287
Drug: oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral scopolamine 1.2 mg
Trial: 3211287
Drug: oral methylscopolamine
RxNorm normalized name: methscopolamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral methylscopolamine 0.6 mg
Trial: 18261569
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose anti-thymocyte globulin (ATG) prophylaxis (4-5 mg/kg)
Trial: 18261569
Drug: Standard immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppressive therapy (cyclosporine, mycophenolate mofetil or azathioprine, and prednisolone)
Trial: 14743647
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids (30 mg/kg/d of methylprednisolone for three to five days with a six-week taper)
Trial: 3279578
Drug: Low-dose steroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose steroids
Trial: 14743647
Drug: Steroids (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (general use)
Trial: 14743647
Drug: Treatments studied
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments studied in adults (applied to children with MS)
Trial: 10817948
Drug: Linguagraph (used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linguagraph (used for therapy and assessment)
Trial: 6096349
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg) plus sulbactam (500 mg)
Trial: 6096349
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg) plus metronidazole (1 g suppository)
Trial: 6096349
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups (A + B)
Trial: 27269661
Drug: Fast-acting refrigerant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-acting refrigerant topical agent (applied for 5 seconds)
Trial: 27269661
Drug: 20% benzocaine
RxNorm normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% benzocaine gel topical (applied for 2 minutes)
Trial: 21890591
Drug: JNJ-37822681 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 at 5 mg
Trial: 21890591
Drug: JNJ-37822681 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 at 10 mg
Trial: 21890591
Drug: JNJ-37822681 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 at higher doses (15 mg and 20 mg)
Trial: 21890591
Drug: JNJ-37822681 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 (various doses)
Trial: 17386348
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment for 2.5 years
Trial: 11431653
Drug: 12-hour myoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour myoglobin < or = 239 ng/mL
Trial: 11431653
Drug: 12-hour troponin-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour troponin-I > 81.5 ng/mL
Trial: 11431653
Drug: 12-hour CK-MB
RxNorm normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour CK-MB > 191 ng/mL
Trial: 11431653
Drug: 12-hour myoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour myoglobin > 239 ng/mL
Trial: 11431653
Drug: 12-hour troponin-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour troponin-I < or = 81.5 ng/mL
Trial: 11431653
Drug: 12-hour CK-MB
RxNorm normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour CK-MB < or = 191 ng/mL
Trial: 9672343
Drug: Hyperphosphate enema
RxNorm normalized name: disodium dihydrogen hypophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperphosphate enema administered 1 and 2 h before the procedure, preceded by a 296 ml bottle of magnesium citrate taken p.o. the night before
Trial: 7974313
Drug: Salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate 50 micrograms twice daily
Trial: 2690316
Drug: SMS 201-995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201-995 (200 micrograms, subcutaneously, 1 ml, three times within 16 hours)
Trial: 2690316
Drug: Isotone saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotone saline (control, subcutaneously, 1 ml, three times within 16 hours)
Trial: 25738850
Drug: ATX-101 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 (2 mg/cm2, total dose 100 mg)
Trial: 21733283
Drug: D-serine (DSR)
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (DSR) 30 mg/kg.d
Trial: 15073698
Drug: Preoperative heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative heparin therapy (POHI group)
Trial: 9589675
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) therapy (approximately 0.22 IU/kg.week) for 24 months
Trial: 7604796
Drug: Fluvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin monotherapy (40 mg/day)
Trial: 7604796
Drug: Fluvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin monotherapy (30.2 mg/day)
Trial: 7604796
Drug: Fluvastatin (39.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (39.3 mg/day) plus cholestyramine (10.3 mg/day)
Trial: 7604796
Drug: Fluvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin monotherapy (32.5 mg/day)
Trial: 7604796
Drug: Fluvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin monotherapy
Trial: 2191507
Drug: Intravenous nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nifedipine (0.8-1.0 mg)
Trial: 506972
Drug: Continental type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continental type breakfast served with coffee (standardized against reference dose of 3 mg Fe from derrous ascorbate)
Trial: 28164407
Drug: BUP‐NLX taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP‐NLX taper
Trial: 25510446
Drug: 70‐kVp and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70‐kVp and CM 64 mL
Trial: 25510446
Drug: 70‐kVp and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70‐kVp and CM 40 mL
Trial: 25510446
Drug: 120‐kVp and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120‐kVp and CM 64 mL
Trial: 25307707
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml ropivacaine 7.5 mg/ml (R group)
Trial: 15191155
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg once daily
Trial: 9718191
Drug: UV-B irradiation
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-B irradiation at half the minimal erythemal dose of the lower back, three times per week during 12 weeks
Trial: 9718191
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 400 IU/day during 12 weeks
Trial: 7651075
Drug: Synthesized all‐trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthesized all‐trans beta‐carotene (60 mg daily)
Trial: 21942184
Drug: Medication (Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Tramadol Hydrochloride Capsules 100 mg)
Trial: 29191951
Drug: Active CPAP
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active CPAP therapy
Trial: 10389123
Drug: Control 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control 0.3% tobramycin solution
Trial: 9049706
Drug: Iloprost treatment
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost treatment
Trial: 1725068
Drug: 6 MU
RxNorm normalized name: Pancrelipase 16 mu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 MU (= 10.4 mg) BM 06.022
Trial: 6847852
Drug: Fructose, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose, 50 g as a 10% solution
Trial: 6847852
Drug: Sucrose, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose, 50 g as a 10% solution
Trial: 31959167
Drug: Budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5 μg
Trial: 28830881
Drug: Allopurinol dose
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol dose escalation (DE)
Trial: 30107437
Drug: Baseline SU
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline SU ⩾ 8 mg/dl
Trial: 15222589
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of alcohol (0.34 g/kg women; 0.4 g/kg men)
Trial: 9451581
Drug: Systemic injections
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic injections of adrenergic antagonist L657,743
Trial: 1839585
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg b.i.d.)
Trial: 25050591
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg infused at Weeks 0, 2, 6, 14, and 22, with escalation to 5 or 7 mg/kg based on EULAR response at Weeks 14 and 22.
Trial: 25050591
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg with dose escalation based on EULAR response.
Trial: 25050591
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment with dose escalation.
Trial: 12654955
Drug: CR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR oxycodone (10 mg tablet every 12 hours, max 60 mg every 12 hours)
Trial: 12654955
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablet every 12 hours)
Trial: 19092248
Drug: CR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR oxycodone
Trial: 1726003
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of lacidipine once daily (n = 220)
Trial: 1726003
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of nifedipine SR twice daily (n = 215)
Trial: 1726003
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of lacidipine once daily (n = 82)
Trial: 1726003
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of nifedipine SR twice daily (n = 62)
Trial: 1726003
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of atenolol once daily (n = 32)
Trial: 1726003
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of atenolol once daily (n = 23)
Trial: 6486846
Drug: Mild topical
RxNorm normalized name: silver protein mild topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild topical antimicrobial wet dressings (Sweitzer's 1:32 solution)
Trial: 25128594
Drug: Topical loteprednol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical loteprednol etabonate and eyelid scrubs with warm compresses (Group I)
Trial: 22669848
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib (Macugen® 0.3 mg = 0.02 mL) combined with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants)
Trial: 22669848
Drug: Conventional laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laser therapy combined with cryotherapy in group 2 (84 eyes of 42 infants)
Trial: 16195124
Drug: Night-time milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time milk containing 10-40 ng/l melatonin, consumed daily for 8 weeks.
Trial: 12869401
Drug: Subjects randomized,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized, sequential order known to the reader
Trial: 10887919
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg/kg) and Alfentanil (10 microg/kg)
Trial: 3318546
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg/kg)
Trial: 10887919
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg/kg) and Vecuronium (0.1 mg/kg)
Trial: 8629746
Drug: HBOC‐201 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC‐201 (45 g)
Trial: 7595029
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (Ringer's lactate)
Trial: 3905222
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac 50 mg 3 times daily
Trial: 3905222
Drug: Proglumethacin 150
RxNorm normalized name: proglumetacin
DrugBank: Proglumetacin (DB13527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumethacin 150 mg 3 times daily
Trial: 29982939
Drug: L‐PRF used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PRF used in addition to another layer
Trial: 26435033
Drug: Insulin initiation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin initiation with glargine, with or without glulisine
Trial: 24773163
Drug: Missing a
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missing a dose of HIV medications
Trial: 23134888
Drug: HSF-DHA diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSF-DHA diet (3.45 g DHA/d)
Trial: 19195454
Drug: Darunavir/ritonavir (800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (800/100 mg once daily)
Trial: 19195454
Drug: Lopinavir/ritonavir (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (once or twice daily)
Trial: 9805325
Drug: Young normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Young normal participants with concurrent memory load
Trial: 7695306
Drug: 882C87 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882C87 200 mg
Trial: 7695306
Drug: 882C87 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882C87 400 mg
Trial: 7695306
Drug: 882C87 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882C87 1600 mg
Trial: 7695306
Drug: 882C87 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882C87 50 mg (elderly)
Trial: 7695306
Drug: 882C87 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882C87 100 mg (elderly)
Trial: 7695306
Drug: 882C87 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882C87 50 to 400 mg